. Author manuscript; available in PMC: 2016 Mar 1.

Published in final edited form as: J Geriatr Oncol. 2015 Feb 7;6(2):133–140. doi: 10.1016/j.jgo.2014.12.002

Table 4.

Distribution of adverse events for the PDR group and standard dose group.

Adverse events	Primary dose reduction	Standard dose	P value
Adverse events	No. (%)	No. (%)	P value
Grades 3–5 toxicity^a	54 (50.5)	212 (53.9)	0.52
Grade 3 toxicity	52 (48.6)	199 (50.6)	0.71
Grade 4 toxicity	8 (7.5)	51 (13.0)	0.10
Grade 5 toxicity	2 (1.9)	7 (1.8)	0.95
Heme toxicity	29 (27.1)	102 (26.0)	0.81
Non-heme toxicity	43 (40.2)	174 (44.3)	0.45
Hospitalization	29 (27.1)	86 (21.9)	0.26
Dose reduction	28 (26.7)	125 (31.8)	0.26
Dose delay	31 (29.0)	124 (31.6)	0.61
Discontinuation of chemo	23 (21.5)	83 (21.1)	0.93

The total n for combined appears lower than the sum of grades 3, 4, and 5 toxicity since only worst toxicity was included in the sum.